NUVECTIS PHARMA, INC.

is a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We are developing two drug candidates, NXP800 and NXP900:

NXP800 is an oral small molecule that exerts its biologic activity through activation of the kinase GCN2. NXP800 is currently investigated in a clinical trial for the treatment of platinum resistant, ARID1a-mutated ovarian cancer, a development program that was granted Fast Track Designation by the U.S. FDA, and for the treatment of cholangiocarcinoma in an investigator-sponsored clinical trial led by Mayo clinic, an indication that was granted Orphan Drug Designation by the U.S. FDA.

NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 is currently investigated in a Phase 1 dose escalation clinical trial.

NUVECTIS PHARMA, INC.

is a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We are developing two drug candidates, NXP800 and NXP900:

NXP800 is an oral small molecule that exerts its biologic activity through activation of the kinase GCN2. NXP800 is currently investigated in a clinical trial for the treatment of platinum resistant, ARID1a-mutated ovarian cancer, a development program that was granted Fast Track Designation by the U.S. FDA, and for the treatment of cholangiocarcinoma in an investigator-sponsored clinical trial led by Mayo clinic, an indication that was granted Orphan Drug Designation by the U.S. FDA.

NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 is currently investigated in a Phase 1 dose escalation clinical trial.

Management Team

Ron Bentsur

Chairman, Chief Executive Officer and President

Enrique Poradosu, PhD

Executive Vice President, Chief Scientific and Business Officer

Shay Shemesh

Executive Vice President, Chief Development and Operations Officer

Board of Directors

Ron Bentsur

Chairman, Chief Executive Officer and President

Ken Hoberman

Director

Matthew L. Kaplan

Director

James F. Oliviero, III

Director

Scientific Advisors

Prof. Shannon N. Westin, MD, MPH

Director, Early Drug Development and Phase I Trials

Prof. Gordon B. Mills, MD, PhD

Director of Precision Oncology, Director of SMMART Trials

Prof. Paul Workman, PhD, FRS

Harrap Professor of Pharmacology and Therapeutics